Advertisement

Topics

FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma

09:48 EDT 17 Apr 2018 | ecancermedicalscience

The U.S Food and Drug Administration has granted approvals to nivolumab and ipilimumab in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. The approvals were based on CheckMate 214...

Original Article: FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma

NEXT ARTICLE

More From BioPortfolio on "FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...

Renal Cell Carcinoma
Renal cell cancer (renal adenocarcinoma or hypernephroma) is the most common type of kidney cancer in adults. More than 8 in every 10 (80%) kidney cancers diagnosed in the UK are this type.  In renal cell cancer the cancerous cells start in the lini...